Bruker Corporation (NASDAQ:BRKR) Q1 2024 Earnings Call Transcript

Bruker Corporation (NASDAQ:BRKR) Q1 2024 Earnings Call Transcript May 2, 2024

Bruker Corporation misses on earnings expectations. Reported EPS is $0.3489 EPS, expectations were $0.46. Bruker Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good morning and welcome to the Bruker Corporation First Quarter 2024 earnings conference call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please also note, today’s event is being recorded. I’d now like to turn the floor over to Justin Ward, Senior Director on Investor Relations and Corporate Development. Please go ahead.

Justin Ward: Thank you, and good morning, everybody. I would like to welcome everyone to Bruker Corporation’s first quarter 2024 earnings conference call. My name is Justin Ward, and I am Bruker’s Senior Director of Investor Relations and Corporate Development. Joining me on today’s call are Frank Laukien, our President and CEO, and Gerald Herman, our Executive Vice President and CFO. In addition to the earnings release we issued earlier today, during today’s conference call, we will be referencing a slide presentation that can be downloaded from the events and presentation section of Bruker’s investor relations website. During today’s call, we will be highlighting non-GAAP financial information. Reconciliation of our non-GAAP to GAAP financial measures are included in our earnings release and are posted on our website at ir.bruker.com.

Before we begin, I would like to reference Bruker’s safe harbor statement, which is shown on Slide 2 of the presentation. During this conference call, we will be making forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to our recent and pending acquisitions, geopolitical risks and wars as well as supply chain, logistics and inflation. The company’s actual results may differ materially from such statements. Factors that might cause such differences include, but are not limited to, those discussed in today’s earnings release and in our Form 10-K for the period ending December 31, 2023, as updated by other SEC filings, which are available on our website and on the SEC websites.

Also, please note that the following information is based on current business conditions and to our outlook as of today, May 2nd, 2024. You should not rely on these forward-looking statements as necessarily representing our views or outlooks as of any date after today. We will begin today’s call with Frank providing an overview of our business progress. Gerald will then cover the financials for the first quarter of 2024 in more detail and share our updated 2024 financial outlook. Now I’d like to turn the call over to Bruker CEO, Frank Laukien.

Frank Laukien: Thank you, Justin. Good morning everyone and thank you for joining us on today’s first quarter 2024 earnings call. I am excited to announce that we have just closed our ELITech acquisition on April 30th, ahead of schedule, after we received all required regulatory clearances, and also after the completion of the pre-closing carve-out of the ELITech clinical chemistry business that we did not wish to acquire. Accordingly, please note that in addition to our earnings release, we simultaneously have issued a second press release this morning, 7 a.m. Eastern, on the closing of our ELITech acquisition. We do encourage you to read both press releases for complementary information and perspectives. As a result, we are pleased to raise our constant exchange rate revenue growth guidance for fiscal year 2024 by 400 bps to 12% to 14%, as explained in detail later during this call.

Turning to our earnings release and Slide 4, Bruker finished the quarter of 2024 with 1.6% organic and 5.5% constant exchange rate or CER revenue growth despite about $15 million of revenue slippage into the second quarter, primarily and primarily because of a rather tough comparison to a very strong first quarter of 2023, in which, if you recall, we posted 17.6% organic growth a year ago. So, keep in mind that we had expected low single-digit organic revenue growth anyway in Q1 because of some pull forward of about 15 — similar pull forward of about $15 million of revenues into the fourth quarter of ‘23 when customer site readiness and shipments just work very well. So underlying demand for Bruker’s products and solutions has remained solid with first quarter ‘24 book-to-build for our BSI segment just below 1.0. So in the second quarter of 2024, we expect a re-acceleration of our organic revenue growth and we also expect double digit, constant exchange rate or CER revenue growth year-over-year.

As expected in the first quarter of ‘24, our margins compressed year-over-year, primarily because of the tough comparison to an unusually strong first quarter of ‘23, but also as a result of transitory factors such as the expected initial margin dilution from our recent acquisitions as well as less favorable mix in this quarter. We expect significant sequential margin improvement in the remainder of the year. As we look to the remainder of 2024 with our solid backlog and pipeline, we expect to achieve above market organic revenue and organic non-GAAP EPS growth. Accordingly, we are maintaining our fiscal year ‘24 guidance for organic revenue growth of 5% to 7%. Since our prior guidance in mid-February, we have closed the Chemspeed acquisition in the first quarter and now the ELITech acquisition on April 30th.

Both are now included in our updated guidance today. As a result, we are increasing our reported revenue guidance by $60 million for reported revenue growth of 11% to 13% year-over-year, and we are increasing our non-GAAP EPS guidance by $0.08 to 8% to 10% non-GAAP EPS growth year-over-year. Please note that our updated May 2 guidance today does not yet include the pending NanoString acquisition, which is expected to be EPS dilutive and which we hope to close in the second quarter. For further information on the pending NanoString acquisition, I refer you to our press release issued on Monday, April 22nd. Continuing On Slide 4, Bruker’s first quarter ‘24 reported revenues increased 5.3% year-over-year to $721.7 million, which included an M&A tailwind of 3.8%.

On an organic basis, revenues increased 1.6%, which included flat organic revenues in our BSI segment and 18.9% organic growth at BEST, net of inter-company eliminations, while the FX headwind was minor at 0.1%. This all implies constant exchange rate or CER revenue growth of 5.5% year-over-year. Our first quarter 2024 non-GAAP operating margin was 14.0%, down 630 bps due to the factors that I described earlier. In the first quarter of 2024, Bruker reported GAAP diluted EPS of $0.35 compared to $0.52 in the first quarter of ‘23. On a non-GAAP basis, first quarter ‘24 diluted EPS was $0.53, down from $0.64 in the first quarter of ‘23. Right, please turn to Slides 5 and 6 now where we highlight the first quarter ‘24 CER performance by our three scientific instruments groups and of our BEST segments all year-over-year.

In the first quarter of ‘24, BioSpin group revenue was $183 million with low single-digit percentage CER growth. BioSpin saw growth across biopharma, academic government, and industrial research markets without any gigahertz class systems in Q1 ‘24 revenue. By the way, in 2024 we expect revenue from three gigahertz class NMRs, including one in the second quarter. We also closed the Chemspeed lab automation acquisition and we will be talking about that further in the future when we update you on our medium-term targets. Moving on to CALID in Q1 ‘24, our CALID group had revenue of $228 million and its CER declined in the low single-digit percentage, primarily to the timing of shipments slipping from Q1 into Q2, as well as to tough comps in the prior year first quarter.

On Slide 6, Q1 ‘24 Bruker NANO revenue was $240 million, and NANO achieved CER revenue growth in the mid-teens percentage, with strong revenue growth in academic government, Aca/Gov, industrial and semiconductor metrology. The artificial intelligence or AI megatrend continues to be a tailwind for our semiconductor metrology and advanced packaging tools business. Finally, Q1 ‘24 BEST CER revenues grew in the high teams percentage, net of inter-company eliminations, driven by solid superconductor demands as well as by growth in big science and fusion research projects, and our emerging key extreme UV or EUV technologies for semiconductor lithography tools by a very large OEM customers, also in support of strong AI demand. Let me take a quick excursion from financials to a couple of further product introductions on Slides 7 and 8.

At US HUPO in the first quarter, we continued with 40 proteomics tools and workflows and software. And in this here we highlight both immunopeptidomes, which are very important in immuno-oncology, and separately glycoproteomics, of course always the 4D versions that we do on our timsTOF platform, and without going into a lot of details here, both of them are excellent examples of things that are not translated in the DNA, they’re not in our genes, at least not in any way that we know. So they’re excellent examples of additional post genomic information that is absolutely needed to understand biology and disease biology. And we are a leader on that same timsTOF platform in 4D proteomics and its applications. The two examples that are both quite important in immunopeptidomics and 4D glycoproteomics.

The other examples are from product introductions that we had at our recent most important NMR conference of the year, the ENC, which was actually in April in California, and we introduced both new enabling scientific capabilities for new scientific capabilities in structural biology, particularly of membrane proteins, of aggregates, of many membrane proteins are important targets or are signaling proteins. And they’re, by the way, they’re also not something that AlphaFold or Cryo-EM or crystallography handle very well. They’re one of the very important areas where NMR plays a crucial role. And again, without scientific details, having ultra-fast spinning probes give us much higher resolution for things that could never be seen before by scientists.

And a separate introduction of a technology for DNP, which stands for dynamic nuclear polarization, can increase sensitivity for some of these methods, in fact by factors of the order of 100. So it’s really game changing and enabling. On the other hand, we also want to make broaden the adoption of NMR and make it much more accessible. A really wonderful new magnet introduction is this Ascend Evo 600 NMR magnet with a one-year helium hold time. This is more than double from before. So it’s quite a technological marvel and again I think it’ll be warmly welcomed by all existing NMR labs but also the new labs in biopharma research, in clinical metabolism, clinical research where previously they hadn’t handled NMR but would like to use it, makes it much more accessible and available for broader markets.

And last but not least, for biotech and biopharma process analytical integration or PAT integration, the Fourier 80, which is our non-cryogenic bench-top FT-NMR, if you recall, has now been more broadly available for this biopharma QC world. All very, very good developments on which we want to update you from time to time. Now, in summary, and as I wrap up my remarks, Bruker delivered solid constant exchange rate growth, albeit with weaker margins and EPS in the first quarter of 2024. We expect some margin and EPS dilution from our acquisitions in 2024 because we have been able to acquire several strategically very important businesses at reasonable valuations. We expect that our Bruker management process applied to these acquired businesses will significantly improve their financial performance over time and drive their long-term profitable growth.

We anticipate also that these strategic acquisitions will enable strong returns on invested capital or ROICs in the future, something that is important to Bruker’s business culture of disciplined entrepreneurialism and also for long-term shareholder value creation. So with those comments, let me turn the call over to our Chief Financial Officer, Gerald Herman, who will review Bruker’s first quarter financial performance in more detail and provide our updated fiscal year ‘24 guidance and assumptions. Gerald?

Gerald Herman: Thank you, Frank, and thank you everyone for joining us today. I’m pleased to provide some more detail on Bruker’s first quarter 2024 financial performance starting in Slide 10, which shows the revenue bridge for the first quarter of 2024. Revenue was up $36 million, 5.3% reflecting organic growth of 1.6%. Acquisitions added 3.8% to our top line, while foreign exchange was a 0.1% headwind, resulting in constant exchange rate revenue growth of 5.5% year-over-year. Frank has already covered the drivers of revenue growth for the quarter. Geographically and on an organic basis in the first quarter of 2024, our America’s revenue grew in the mid-single-digit percentage, European revenue grew in the high single-digit percentage, Asia Pacific revenue declined in the single digit percentage range, primarily due to softness in Japan, all year-over-year.

For our EMEA region, first quarter 2024 revenue was up mid-teens percentage year over year. Slide 11 shows our Q1 2024 P&L performance on a non-GAAP basis. Non-GAAP gross margin of 51.2% decreased 220 basis points from 53.4% in the first quarter of ‘23, impacted primarily by mix, acquisition and FX headwinds and a challenging prior year comp. First quarter of 2024 non-GAAP operating margin of 14.0% was 630 basis points lower than the 20.3% margin we posted in the first quarter of 2023. This decline is attributable to most of the same factors impacting gross margin, product mix, acquisition and foreign exchange headwinds, and a challenging prior year comp. We expect Bruker’s non-GAAP operating margins to improve sequentially in the second quarter and significantly in the second half of 2024.

For the first quarter of 2024, our non-GAAP effective tax rate was 26.7%, a modest improvement from the 27.8% in the first quarter of 2023, resulting from favorable jurisdictional mix. Weighted average diluted shares outstanding in the first quarter of 2024 were 145.9 million, a reduction of 1.7 million shares or 1.2% from the first quarter of ‘23, resulting from our share repurchases. Finally, Q1 2024 non-GAAP EPS of $0.53 was down 17.2% compared to the first quarter of 2023, primarily due to the margin compression factors previously detailed. We experienced about $0.05 of non-GAAP EPS dilution from the Bruker Cellular Analysis, formerly PhenomeX, acquisition in the first quarter of 2024. With the rightsizing actions we’ve already taken, we expect our BCA business to reach breakeven by 2026.

We generated $21.8 million of operating cash flow in the first quarter of 2024. Our capital expenditure investments were $21.4 million, resulting in free cash flow of $0.4 million in the first quarter of 2024. This reflects a decrease in cashflow of approximately $62.1 million over Q1 of ‘23, driven by lower net income and higher working capital levels, mostly impacted by our recent acquisitions. We finished the first quarter with cash, cash equivalents, and short-term investments of approximately $340 million. During the first quarter, we used cash to fund acquisitions, capital expenditures, and select Project Accelerate 2.0 initiatives. In the first quarter of 2024, we completed a series of debt financing actions to fund our recent acquisitions, including the larger ELITech transaction.

We upsized our evolving credit facility to $900 million, issued CHF431 million private placement senior notes with 10, 12 and 15 year maturities at average interest rates of about 2.6% and closed on a CHF450 million term loan structure with 5, 7 and 10 year maturities carrying interest rates of about 3%. These financings provide us with flexibility to support strategic acquisitions like ELITech and our pending NanoString acquisition and de-lever over time. Turning now to Slide 14, we are maintaining our organic revenue growth guidance and organic non-GAAP EPS prior guidance from February 13, ‘24. We’re updating our 2024 outlook to include the recently closed acquisitions of ELITech and Chemspeed, as well as changes in foreign currency. It does not include the pending NanoString acquisition, which was covered in our April 22nd press release.

Our updated guidance for reported revenue is $3.29 billion to $3.35 billion, up $60 million from prior guidance, representing growth of 11% to 13% compared to 2023. As noted earlier by Frank, this guidance maintains our full year ‘24 organic revenue growth of 5% to 7% year-over-year. It also reflects an estimated foreign currency headwind of about 1% and acquisitions contributing now about 7% to revenue growth year-over-year. This guidance now implies constant exchange rate, CER revenue growth of 12% to 14% in full year 2024 year-over-year. For non-GAAP operating margins in 2024, following strong organic operating improvement of about 130 basis points in 2023, we expect 2024 organic operating margin improvement of about 50 basis points. For non-GAAP operating margins all in, we expect about a 60 basis point decline from the prior year due to a combined acquisition and foreign exchange headwind of about 110 basis points.

As we explained in the simultaneous ELITech closing press release this morning, we expect ELITech to be immediately accretive to Bruker margins. On the bottom line, we’re now guiding to non-GAAP EPS for 2024 in a range of $2.79 to $2.84, up $0.08 from the accretive ELITech acquisition. This translates to non-GAAP EPS growth guidance of 8% to 10% compared to 2023. Other guidance assumptions are listed on the slide. Our fiscal year 2024 ranges have been updated for foreign currency rates as of March 31, 2024. One additional note on quarterly phasing for the year. We expect second quarter organic revenue to be up mid-single-digits organically year-over-year. We also expect to see sequential improvement in non-GAAP operating margin performance in the second quarter of 2024 and significant improvement in the second half of 2024.

We expect to host a follow-up call with investors and sell-side analysts within a few weeks after the closing of our NanoString acquisition. During this call, we plan to provide additional information on our recent significant acquisitions, including Chemspeed, ELITech, and NanoString, and update our medium-term outlook for fiscal year 2026 financial targets. Finally, I echo Frank’s earlier comments on the importance of these recent acquisitions. While we expect some margin dilution initially from certain acquisitions, these are excellent additions to complement the portfolio transformation underway at Bruker and expected to contribute solid profitable growth and strong ROIC performance to our shareholders over the next few years. To wrap up, Bruker delivered solid, constant exchange rate revenue growth in the first quarter of 2024 and we’re well positioned to deliver above market revenue growth and organic non-GAAP EPS growth in 2024.

With that, I’d like to turn the call over to Justin to start the Q&A section. Thank you very much.

Justin Ward: Thank you, Gerald. I’d now like to turn the call over to the operator to begin the Q&A portion of the call. As a reminder, to allow everyone time for questions, we ask that you limit yourself to one question and one follow-up. Operator, we’re ready for the Q&A portion.

See also Top 10 Artificial Intelligence (AI) SEO Tools in 2024 and 13 Best Reddit Stocks to Buy Now.

Q&A Session

Operator: We will now begin the question-and-answer session. [Operator Instructions] Our first question today comes from Puneet Souda from Leerink Partners. Please go ahead with your question.

Puneet Souda: Hi, Frank, Gerald. Thanks for taking the questions. My first one is on the revenue slip as you talked about. Is that just a pull forward into the 4Q ‘23 and thus not expected going forward? And just overall with the mid-single-digit expectations for the second quarter, can you just elaborate what you’re seeing in terms of the overall demand, your ability to deliver from the backlog and any bookings growth that you can talk about? And then I have a follow-up.

Frank Laukien: Yeah, thank you, Puneet. It’s Frank. So yeah, as you recall, our Q4 of last year was strong, even stronger than we had expected. Usually something slipped into Q1 and all the site readiness and export permits, I mean, nearly everything went flawlessly. And so, yeah, with that, we had already expected a low single-digit organic revenue growth for Q1, and we had signaled that previously. And then it was a little lower than we would have liked with about $15 million, that’s slipping into Q2, which is what we acknowledged here. There’s essentially no risk of any of that getting canceled that will come in in Q2. Those were the usual export permits, site readiness, or sometimes, some logistical issues that the system does not go in, but there’s no risk issue and it’s not a reflection of any demand.

With that, we ended up at the 1.6% organic growth, which is a bit weaker than we would have liked. But as always, it’s best to look at Bruker as an average over several quarters. And I think we’ll have a decent mid-single-digit or perhaps better Q2 organic revenue growth and expect double-digit CER growth in the second quarter. So that’s the cadence.

Puneet Souda: Got it. Super helpful. And then, Frank, I mean, I can’t recall a time when Bruker had these many number of acquisitions in such a short period of time. So, look, first of all, it’s great to see you picking up a number of these excellent technologies for the post-genomics era that you’ve talked about, but two questions that investors are struggling with, when we look at what do these acquisitions mean for potential dilution, and I know you’re going to talk about that on the follow-up call, but any sort of directional read that you can provide us on into how to think about these in 2025? And then, more importantly, I mean, if you could elaborate a bit on how your plans are looking in terms of integration priorities, and — because it does seem like there’s significant undertaking versus what Bruker might have done in the past and that is likely to have some impact on the inorganic growth and EPS in the near term and medium term as well.

So maybe just talk to us about the integration and how are you thinking about that?

Frank Laukien: Yeah, so I’ll sort of do it in reverse order, Puneet. We’re actually very confident on the integration and that we have the bandwidth to do this. It turns out because we are — we have three very strong groups of — plus BEST, we really have the management capacity and integration capacity as if we were almost three companies. I mean obviously we’re one company but it turns out the ELITech business and a number of these smaller acquisitions that were done by our Bruker Optics Division previously, that’s all within CALID and they’re handling that really except for financing and some high level corporate matters really. Very, very focused and they’re — and I’m convinced they’re going to handle that very well and they’re handling very well the smaller ones that they’ve done already.

Chemspeed and some of these software acquisitions that you’ve seen recently are very much part of the BioSpin Group. So we have a really a separate group. It’s kind of a modular setup where they’re pursuing that and really are doing a great job with that. So again, it doesn’t — it’s not that these things are all piling up on us except at the highest level where we provide the strategic direction and the support and the financing of course. And ultimately, and that’s where there’s more work to be done. I mean we did not expect either that we would be able to acquire the former PhenomeX, now Bruker Cellular Analysis, and then that NanoString would already in Q2 run into their Chapter 11 reorganization. And so, this wasn’t going to wait till Q4 or till we get around till next year, this was an opportunity — a strategic opportunity that’s incredible in a complicated situation.

We’ll admit that, but on the other hand, what an opportunity to build, to buy not only a gene expression business, their gene expression business with encounter is quite nice, but really a hopefully closed soon, I mean this hasn’t closed yet, but to acquire hopefully soon and it’s under agreement in an asset deal the spatial biology business which is one of the leading spatial transcriptomics businesses as you know. So those were incredible strategic opportunities and again evaluations that are absolutely compelling and will lead to great ROICs. So that is very unusual for Bruker to have that many acquisitions. On the other hand, the opportunities that we had and the flexibility and the organizational bandwidth that we have allow us to do that.

On ‘25 and ‘26, if I may defer you to this little mini Investor Day that we hope to do within, as a virtual call only, within weeks after we close NanoString. Hopefully we get to close NanoString in the second quarter and then hopefully within weeks, Justin will be setting up a two-hour call where we present and have the division leaders of those new businesses present Chemspeed, present ELITech and hopefully present NanoString and then of course Gerald and I will wrap it all up and tell you how that affects and accelerates our medium term outlook for 2026. That’s our present plan. Other than that, we prefer not to comment on NanoString today because it’s still pending and as you know we tend to be very disciplined. Now we talk about ELITech now that it’s closed and we’ll talk about NanoString more when that closes hopefully in the second quarter.

Puneet Souda: Got it. That’s fair. Thanks, Frank.

Frank Laukien: All right. Thank you, Puneet.

Operator: Our next question comes from Patrick Donnelly from Citi. Please go ahead with your question.

Patrick Donnelly: Hey, guys. Thanks for taking the questions. Frank, maybe just one on kind of the order backdrop, a little more real time. It sounded like the book-to-build is a little bit below 1 in DSI. Can you talk about what you’re seeing on the order front, maybe on the academic side in particular, what the conversations there with customers are, and just expectations as we go forward here?

Frank Laukien: Yeah, we didn’t use up much backlog in the first quarter because of some revenue slippage, so our backlog coverage is still about 7.5 months, so that’s remained strong. And academic government in the US and in Europe has been decent. We’ve had also reasonable, except for China, reasonable bookings in biopharma, diagnostics, MALDI Biotyper is doing well, certainly on the consumable side. So it’s not a fantastic macro environment out there, right? But it’s decent and its sort of the bookings and in all the various markets, geography or by market, by end market are about as expected, which is slower growth but still organic growth for us. And yeah, so the macro environment isn’t exciting, but it is also not deteriorating and it is about as we expect it given our tool set and portfolio transformation, which as you’ve seen, does allow us with above-market 5% to 7% organic revenue growth this year. We’re really quite confident with that.

Patrick Donnelly: Okay, that’s helpful. And then maybe you touched on China briefly in the answer there. Can you just talk about the trends over there? I mean, there’s been some debate about stimulus loan program, whatever you want to call it. What you’re seeing there, what the conversations look like in China, and expectations for the year would be helpful. Thank you.

Gerald Herman: Patrick, it’s Gerald. I’ll take this one. So from a perspective of China, I mean, our — we’re — it’s still early days, I guess I’d say with respect to this loan stimulus program that’s being considered. We’ve heard some conversation on the street about how that’s going to play out. We don’t expect to see that transfer itself into real orders probably until certainly the second half. Our understanding is that it’s a relatively broad stimulus program targeting equipment upgrade and certainly in the technology area over multiple years, our expectation is that will ultimately result in a tailwind for Bruker. But we don’t really have any further details on exactly the timing or exactly which products would be impacted. That’s what I guess I can say about that. We still continue to feel pretty strong about the overall performance in China over time, but obviously there’s been some challenges there from a macro perspective.

Frank Laukien: Very fundamentally, China has again remade and clarified their very strong and exceptionally strong commitment to science and technology. And that’s a very high priority for them and for their investments as a country, which bodes well for the entire industry. It also does bode quite well for us with more of an academic government exposure or I mean more participation in China, whereas we got a little lucky that we’re not so exposed to their biopharma or CRO markets, which obviously have been and probably continue to struggle to some extent also because of geopolitical risks. Anyway, so that’s bypassing us mostly.

Patrick Donnelly: Thank you, guys.

Operator: Our next question comes from Rachel Vatnsdal from JPMorgan. Please go ahead with your question.

Rachel Vatnsdal: Perfect. Hi. Good morning, you guys. Thanks so much for taking the questions. So first I wanted to push a little bit on this 2Q guide. You mentioned that you’re expecting mid-single-digit organic growth next quarter. So that came in a little bit lighter than expectations. You also mentioned that $15 million flipping from 1Q to 2Q. So can you help us understand the puts and takes there? What are the underlying assumptions embedded in 2Q? Is there any level of conservatism or is this more of a realistic guide based on what you’re seeing in the market right now?

Frank Laukien: Yeah, no, I mean, hopefully it’s in the — it’s, sorry, mid-single-digit is somewhat conservative guy because we just missed a little bit in Q1, right? So we’d like to not have that repeat, but, so there’s some upside to that. But on the other hand, it’s also realistic — it’s a realistic color for the second quarter with potential for upside, but we’d like to be in an area where there’s no downside to that in Q2.

Rachel Vatnsdal: Okay, great. That’s helpful. And then just on 2025, you’ve pulled forward some of the 2025 — or the 2026 estimates to 2025 last quarter. I appreciate you’re going to host this mini Analyst Day in the coming months here. But I guess just to clarify, are you assuming that any of the underlying assumptions within that 2025 framework that you touched on last quarter have changed, or are you really just pointing towards an update given some of the recent M&A and deals closing between ELITech and NanoString on the horizon?

Frank Laukien: Yeah, it’s all about M&A, Rachel. So, Chemspeed this year adds about $10 million per quarter in revenue and is neither EPS dilutive nor accretive. We think by next year, they’ll be somewhat EPS accretive and get back into growth mode. They had a lot of changes going from switching to US GAAP and product accounting rather than percentage of revenue. Too much detail and we’ll give you more at our mini Investor Day there or mini investor call. So they’ll be [more decretive] (ph). ELITech will be, it looks like it continues to be a very nice high single-digit, sometimes low double digit organic revenue growth business and clearly somewhat margin accretive, clearly EPS accretive. So that all comes in. And then, as we close — when we close NanoString, as we have spelled out without a lot of detail, but just as a heads up in our April 22nd announcement of the Asset Purchase Agreement for NanoString, we won’t give ‘24 guidance on NanoString for reasons explained in that press release.

Obviously, it had considerable disruption from Chapter 11 and other litigation related materials. We will get into that today. So we’ll see how that business settles. We just want to give the Street a heads up that there is a meaningful valuation from that in ‘24. We estimated $0.15 to $0.20. Happy to take that next year. We expect that to be lower next year, but we’re not going to be able to go into that today, right, because it hasn’t closed. So it’s all fundamentally, all the incremental changes are all about these acquisitions. And I guess the supporting financing that we’ve done at — that Gerald has done at incredibly extractive rates with our banking partners, very, very pleased with how our capital structure is supporting all of that in a very attractive way.

So we’ll pull all of these things together because they are too many moving pieces for you all, quite honestly, to be able to try to figure it all out. So we’ll hope to really assist you with that and give you the ability to then model ‘26 and ‘25 in between, although we’re not going to give ‘25 guidance. But I think you’ll be in a much better position to understand how all these pieces come together.

Rachel Vatnsdal: Great. Thank you for all the color.

Operator: Our next question comes from Doug Schenkel from Wolfe Research. Please go ahead with your question.

Unidentified Analyst: Hi, thanks for the question. This is Colleen on for Doug. I just want to know how you’re framing book-to-bill normalizing for the bolus in China stimulus bookings in Q1 of last year and the timing of delay of bookings in Q1?

Justin Ward: So the book-to-bill is for the first — the book-to-bill that Frank quoted of roughly 1.0 is for the first quarter of this year. Right? So that bodes well now. Last year in China, we had a bolus of orders in the first quarter, But then we had basically an air pocket of orders in the third quarter of last year from China. So there was a lot of distortion in bookings in China last year. For the full year in last year in China, we had bookings up nicely in the double digits along with revenues. So as you look at 2024, there’s quite a bit of distortion on the year-over-year comp in China for bookings. And for that reason, we really think it makes sense to look at kind of full year picture from bookings. Hopefully that’s helpful.

Unidentified Analyst: Thank you. And just 1 follow up on leverage. So with the NanoString deal, we estimate your debt to EBITDA will approximate about 3.5 times. Is that right? And if so, is it fair to assume this is the limit of what you’d be willing to take the balance sheet?

Gerald Herman: We’ll talk more about that, actually, in the mini Investor Day. But what I’d say is, first of all, we need to make sure we’re talking about gross versus net on the calculation. And we’ll talk, again, I think I’d just defer that to our call coming up. I mean, overall, of course, we’re pleased with the financing actions we’ve already taken, and we’ll talk more about options as we march into the forward investor and sell-side analyst discussion.

Frank Laukien: But approximately, with your question, you’re approximately right. Leverage — gross leverage of about 3.5, net leverage will be lower. And generally that’s not where we normally operate, we prefer to operate more in the 2.0 to 2.5 range. And, obviously there will be time, there will be opportunities to de-lever. Very clearly our goal will be to de-lever from that level again.

Unidentified Analyst: Thank you.

Gerald Herman: You’re welcome.

Operator: Our next question comes from Jack Meehan from Nephron Research. Please go ahead with your question.

Jack Meehan: Thank you. Good morning. I had a couple of…

Gerald Herman: Good morning.

Jack Meehan: …financial questions for you guys. On the income statement, did you just explain, I guess, like below the line, other income, I was modeling like $7 million of other expense, but it was kind of the opposite. Were there any factors that drove then the quarter?

Gerald Herman: One of the other significant items coming out of the quarter is, of course, as you likely know, we moved a series of — took a series of actions on the foreign exchange side to be able to secure the EUR870 million ELITech transaction. So that’s part of what you see there. There’s a substantial foreign exchange gain that came between the euro and the Swiss franc. So that’s what you see. We also had, as I think I mentioned in my prepared remarks, a more favorable tax rate than we had in the prior year. Fundamentally, I’m pleased with that from a jurisdictional mix perspective. So those are the tow pieces.

Jack Meehan: Great. Okay, that makes sense. And then the second question was just on the PhenomeX dilution. Could you talk about just how the integration is going, number one? Number two, I think I heard $0.05 of dilution. Previously we were talking about $0.02 to $0.03 a quarter. Just what was the delta there?

Frank Laukien: Yeah, PhenomeX, or now as we call it, Bruker Cellular Analysis, we are estimating $0.10 to $0.12 dilution for the year, ‘24. If you recall, we had $0.14 of dilution in Q4 before we could, we triggered the warrant act. So it took us, while we made the decisions right away, it took us some time to reduce headcount and cost. And some of that also still outside of the United States, some of that cost reduction takes a little longer to have an effect. So yeah, $0.05 was the number, correct, for PhenomeX. And the average this year may be $0.02 to $0.03, or maybe $0.03 on average, but it will be more front-loaded. So good catch again, Jack. It was higher than the average in Q1.

Justin Ward: Yeah, Jack, as you’d imagine, the dilution is going to gradually taper from PhenomeX over time. What we’ve said is we expect it to be basically break-even by 2026. But a lot of that dilution will really taper off in the first half of this year.

Gerald Herman: Right.

Justin Ward: So that’s how we’re thinking about the — yeah.

Jack Meehan: Sounds good. Thank you, guys.

Gerald Herman: You’re welcome.

Operator: Our next question comes from Dan Brennan from TD Cowen. Please go ahead with your question.

Dan Brennan: Great. Thank you. Thanks for taking the question. Frank and Gerald, I know we’re going to get more color on NanoString once it closes, but is it possible to speak at all to the work that you’ve done on the patent situation just because I think that likely caught many people by surprise the fact that they’ve got these cases ongoing and they lost the GeoMx case earlier this year, which obviously they’re appealing and they have the CosMx case. I’m just wondering any color you can provide on the work you did, the comfort you got and/or any remedies you might have in place if these cases go against NanoString?

Frank Laukien: Yeah, that’s really something we were — at first of all talking, we’re not going to talk even after the closing about litigation, our potential litigation outcomes or litigation strategies. Today we certainly cannot talk about it because it hasn’t even closed. It’s obviously a key issue for the NanoString company, right? I mean that, to a significant extent, drove them into Chapter 11 reorganization. Then once they were in the Chapter 11 reorganization, I’m not telling you anything you don’t know, there was a favorable interim ruling at the European Patent Court that lifted the CosMx preliminary injunction, at least outside of Germany, if I have all my facts right. So there’s been some positive news. But, that’s all intermediate, subject to appeal, subject to final ruling.

So there is a lot of moving pieces and a lot of separate litigations and challenges and dirty hands and antitrust counterclaims and all of that and how that plays itself out we can discuss a little bit more. And hopefully we don’t spend our entire mini, we will not, I promise you, spend our mini Investor Day on IP items, but we can give you a little bit more color to the extent we can’t comment on ongoing litigations which is very limited as you might guess.

Gerald Herman: We are aware.

Frank Laukien: We are very aware. We are very aware.

Dan Brennan: Okay. And maybe just one on the semi-business. You called out the AI-related positioning. Just wondering if you can help us kind of size that. Like, how did semis do in the quarter? Any specific color on how much that AI is driving your semi and packaging business? And kind of, what do you kind of assume implicit in the guide for the year? Thanks.

Frank Laukien: Now, we tend to do that more on an annual basis because of course quarterly fluctuations, but I think our semiconductor metrology business as a total percentage of revenues is now in the high single-digits and probably marching towards, eventually towards 10% and higher. And maybe the, and so that’s did well in terms of revenues in Q1. The additional piece that that’s still, modest and below 1% of our revenue, is that we now, via BEST and their research instrument subsidiary, participate in the semiconductor — the Extreme UV or EUV technologies are now going into lithography, which is, of course, semiconductor manufacturing for smaller and smaller feature sizes which are needed, particularly for AI, but also perhaps for other high-performance computing applications.

And there are some unique technologies where we’re simply in the supply chain. We don’t deliver complete systems of the largest lithography supply chain that is out there. Anybody can guess who that might be. And we’re very pleased we’re providing some unique technologies from our research instruments business. And I’m sure you’ve never heard of, but it’s not insignificant anymore. Maybe it’s $20 million or something like that in the supply chain. These aren’t systems, but it’s a very, very key and very unique technology position that just adds a little bit of cherry on top of our semiconductor and advanced packaging metrology business that you’re more familiar with. Yeah, this is just — that’s a very good trend, and it’s unusual for a life science or post-genomic company.

But indeed, we have it in our nanotools, to some extent, are just very applicable and very unique there. It’s wonderful.

Dan Brennan: Great, thank you.

Frank Laukien: You’re welcome, Dan.

Operator: Our next question comes from Dan Arias from Stifel. Please go ahead with your question.

Dan Arias: Good morning guys, thank you. Frank, I really do apologize for asking this because you said you’ll be addressing NanoString later and so this may be an unfair question. But if I…

Frank Laukien: Let’s not believe [indiscernible] go ahead Dan, sorry.

Dan Arias: It’s less about the details and the financials and more just about the rationale. Can you speak to whether this is a deal where you just felt like the price is right to your point earlier or one where the diligence led you to a point where you felt like you were comfortable either with the legal side of the equation or the technical side of the equation and work around for some of the problems that are actually leading to the legal side. Can you just talk a little bit about how comfortable you got with the deal? Because obviously, it is a controversial one. Thanks a bunch.

Frank Laukien: Yeah, so probably the answer is no, because I don’t want to talk about any of the litigation and all of these other things. But strategically, having a much bigger play in spatial biology with being able to acquire at a very reasonable valuation one of the two leaders in spatial transcriptomics is an unbelievable strategic opportunity. That’s completely what drives this deal. We’re very pleased with their gene expression and counter-profiling business. We think that has some growth opportunities. It has good margins, wonderful. But the driver was spatial transcriptomics. So the GeoMx and CosMx and related product, software and other product lines. And that is a really big deal if you want to be a leader in spatial biology.

We have a complementary but much much smaller spatial proteomics business with Canopy. They really are in adjacent markets. They don’t really overlap. They’re also — what NanoString is doing is, a hundred times larger. So this really puts us on the map in spatial transcriptomics. We like their plexing capability, a lot of research customers, that’s really what they want, they’re far ahead and I think they’re pretty fundamentally ahead in spatial transcriptomics. So, they’re one of the pioneers and we want to continue to support their customers in doing their fundamental and then very much also the translational clinical research where these spatial single cell transcriptomics tools are so needed for biomedical research and that’s a — in addition to proteomics and structural biology, glycoproteomics, spatial biology in there, the bigger field is spatial transcriptomics and we had no presence in that.

So for us this is a huge opportunity, and we seized it.

Dan Arias: Okay. Appreciate you indulging me on that. And then I guess just the natural next question or one of them anyways is, are you still on the hunt for deals? Are they likely to do additional M&A from here? Thank you much.

Frank Laukien: I think we’re going to be in the deal diet for a little while. I mean there’s always small deals that come through, , sometimes that a lot of the smaller deals sometimes some of them at $5 million or $10 million in revenue and some of them were literally addressing gaps that we had in our product line in preclinical imaging or in Raman process analytical technology or high-end Raman microscopy, those are things that we’ve been eyeing for many years and sometimes more than a decade and when some of the companies then became available that fit perfectly into our optics or into our BioSpin preclinical imaging, we said, wow this is great and yeah it all comes at the same time. Whereas two years ago, it was very difficult with valuations then to agree on anything.

So we are value conscious, we are ROIC conscious. And so yeah, this is a — but in terms of larger deals, we obviously need to — we do wish to then de-lever for a while and that’s — I think that’s the answer on larger deals. I would not expect any additional larger deals until we de-lever some.

Dan Arias: Thank you, Frank.

Frank Laukien: You’re welcome, Dan.

Operator: [Operator Instructions] Our next question comes from Josh Waldman from Cleveland Research. Please go ahead with your question.

Josh Waldman: Hey, good morning, guys. Thanks for taking my questions. I’ll ask two and then hop off. First, Frank, can you comment on year-over-year orders in DSI and 1Q and whether the guide assumes any sequential improvement in order rates from here? I guess just more context on how you’re thinking about the order cadence to support the full year organic guide would be helpful. And then for my follow up, Frank, again, wondered if you could comment or provide more context on the moving pieces within the CALID business. Maybe more color on the revenue slippage. You mentioned tougher comps. I can’t help but notice you didn’t highlight timsTOF this round. Yeah, I guess just any more context you’re being on the order front. How you’re thinking about timsTOF growth and any other kind of one-off or one-time pressures the segment may have seen this quarter.

Frank Laukien: Yeah, so trying to take as many of the questions. So, bookings, I think we expect the normal seasonality that we have with bookings always weakest in Q1, strongest in Q4, and in between in Q2, Q3, they tend to be more comparable in terms of booking. So that’s what we expect this year as well. So normal booking seasonality to where, to your first question, I think would imply a sequential step up, not only revenues and margins, which we’ve mentioned, but also in bookings throughout the remainder of the year. timsTOF, I did mention, of course the 4D proteomics and immunopeptidomics and glycoproteomics, that’s all. There was a picture of a timsTOF Ultra, that’s all in the timsTOF platform. Very significant workflow and software and capabilities increases that we showed at the US HUPO meeting in March.

We have an ASMS around the corner, right, that’s coming up in the second week of June in Anaheim. So that’s obviously a biggie in the mass spec world and timsTOF is doing well. And the many platforms and the many new capabilities, it’s just such a beautiful platform. As you peel the onions, there’s not only proteomics and then maybe plasma proteomics or single cell proteomics and now there’s middle down, top down. There is intact. There are these immunopeptidomics and unique PTMs and glycoproteomics. There’s protein-protein interactions. It’s such a rich field that one really now has to look at like a dozen subfields that all constitute proteomics and related fields, and the instrument is very, very suitable for that and along with new wetware consumables, with new software, with new workflows, so plenty going on there.

Josh Waldman: Frank, I guess just on the revenue slippage, was that timsTOF or is it something else within CALID?

Frank Laukien: No, it was also not only CALID and also with semiconductor metrology tools. Sometimes when one of these facilities by one of our large semiconductor metrology tools gets slips by a quarter or two and those very large customers that you all know by name tell you know, they’ll ship that in March, ship that in, whatever, and Q2 and stuff like that. So some of that was that. Some of that was NMR and preclinical imaging, MRI related. So this wasn’t just — this was not just on CALID, but CALID had a very strong pump year-over-year, I think, one of the strongest.

Justin Ward: And Q4, there was quite a bit pull forward into Q4, including within, for example, the optics business, which is within CALID. So those cause quite a distortion and is the primary driver of the lower organic growth in the first quarter.

Frank Laukien: Correct.

Josh Waldman: Got it. Okay. Appreciate it, guys.

Justin Ward: All right, operator, I think we’re all set with questions. So we want to thank everyone for joining us today on the call. Bruker’s leadership team looks forward to meeting with you at an event or speaking with you directly during the second quarter. Please feel free to reach out to me to arrange any follow ups. Have a great day.

Operator: Ladies and gentlemen, with that, we’ll conclude today’s conference call and presentation. We thank you for joining. You may now disconnect your lines.